FIGURE 2.

Peptide 17 reduces SBP and modulates biochemical parameters of kidney injury in hypertensive rats. (A) Body weight. (B) Ratio of kidney weight/body weight. (C) Creatine content in plasma. (D) NGAL in plasma. (E) Urine volume. (F) Albumin content in urine. (G) Albumin content in urine. (H) NGAL in urine. (I) SBP in different groups. The one‐way ANOVA followed by Tukey's multiple comparison posttests was performed. For A‐H, *p < .05 compared with WKY group; the significance difference for other group comparisons is reported in the figure panels. For I, * in orange indicates p < .05 in the comparison of SHR + ctrl siRNA with WKY, * in red indicates p < .05 in the comparison of SHR with WKY, * in green indicates p < .05 in the comparison of SHR+ peptide 17 with SHR, * in black indicates p < .05 in the comparison of SHR+ YAP siRNA with SHR. The results were obtained from six rats/group